Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia

Acta Psychiatrica Scandinavica

Volumn 126, Issue 1, 2012, Pages 1-11

  Hutton, P ^a,b   Morrison, A P ^a,b   Yung, A R ^c   Taylor, P J ^b   French, P ^a,b   Dunn, G ^b  

^a GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antipsychotics; Meta analysis; Randomised controlled trial; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

COCHRANE LIBRARY; DRUG EFFICACY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATA INTERPRETATION, STATISTICAL; DIBENZOTHIAZEPINES; HUMANS; PATIENT DROPOUTS; PIPERAZINES; QUINOLONES; REVIEW LITERATURE AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE;

EID: 84862140672     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01858.x     Document Type: Review

References (71)

1. Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009;373:4-5.
2. NHS. Schizophrenia data focussed commentary. NHS National Prescribing Centre, 2009. Available from: Accessed 15th June 2010.
3. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
4. Jadad AR, Cook DJ, Jones A et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998;280:278-280.
5. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
6. Jørgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 2006;333:782.
7. Cumptson M, Clark K. The dissemination of Cochrane evidence. An inventory of resources that use Cochrane reviews. Canadian Cochrane Centre on behalf of The Cochrane Collaboration, 2004. Available from: Accessed 15th June 2010.
8. Higgins JPT, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions. Chichester, UK; Hoboken, NJ: Wiley-Blackwell; 2011. Available from: Accessed 13th August 2011.
9. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305-1312.
10. Rabinowitz J, Davidov O. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 2008;34:286-291.
11. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry 2006;59:1001-1005.
12. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009;166:639-641.
13. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials Mol Psychiatry 2009;14:429-447.
14. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008;34:275-285.
15. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet 2002;359:781-785.
16. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone, 2000.
17. Xia J, Adams CE, Bhagat N et al. Losing participants before the end of the trial erodes credibility of findings. Psychiatr Bull 2009;33:254-257.
18. Bleakley S, Olofinjana O, Taylor D. Which antipsychotics would mental health professionals take themselves? Psychiatric Bull 2007;31:94-96.
19. Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev 2010;1:CD006918.
20. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD001359.
21. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2:CD000967.
22. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578.
23. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev 2002;2:CD001357.
24. Lecrubier Y, Bouhassira M, Olivier V, Lancrenon S, Crawford AM. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schlzophrenia. Eur Neuropsychopharmacol 1999;9:S288.
25. Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006;114:319-327.
26. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-167.
27. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
28. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218.
29. Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152:130-134.
30. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690.
31. Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsychotic: overview of a phase II study result. Int J Neuropsychopharmacol 2000;1:S157.
32. Marcus RN. Efficacy and safety of lower doses of aripiprazole. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26 Atlanta, USA. 2005.
33. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets, medical review. US Food and Drug Administration Centre for Drug Evaluation and Research, 2002. Available from: Accessed 17th June 2010.
34. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056.
35. Tollefson GD, Dellva MA, Mattler CA, Kane JM, Wirshing DA, Kinon BJ. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. J Clin Psychopharmacol 1999;19:435-443.
36. Chouinard G, Jones B, Remington G et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
37. Honer WG, Thornton AE, Chen EY et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
38. Fabre LF Jr, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204, 636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378.
39. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006;189:102-108.
40. Daniel DG, Stock EG, Wilber CH et al. Intramuscular aripiprazole in acutely agitated psychotic patients. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA. APA Conference Abstracts NR612, 2004.
41. Oren D, Marcus R, Kostic D, Mcquade R, Iwamoto T, Archibald D. Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder. Schizophr Bull 2005;31:499.
42. Carson WH, Ali M, Dunbar G, Ingenito G, Saha AR. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophr Res 2001;2:221-222.
43. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
44. Potkin SG, Gharabawi GM, Greenspan AJ et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85:254-265.
45. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325.
46. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006;114:3-13.
47. Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49-55.
48. Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. Acta Psychiatr Scand 2011;123:459-465.
49. Lieberman JA, Stroup TS, Mcevoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
50. Beasley CM Jr, Sutton VK, Hamilton SH et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582-594.
51. Kryzhanovskaya L, Schulz SC, Mcdougle C et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:60-70.
52. Marques TR, Arenovich T, Agid O et al. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011;41:1481-1488.
53. Bola JR. Medication-free research in early episode schizophrenia: evidence of long-term harm? Schizophr Bull 2006;32:288-296.
54. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007;195:406-414.
55. Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr Serv 2008;59:487-496.
56. Leff J, Sartorius N, Jablensky A, Korten A, Ernberg G. The International Pilot Study of Schizophrenia: five-year follow-up findings. Psychol Med 1992;22:131-145.
57. Hopper K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. Schizophr Bull 2000;26:835-846.
58. Cohen A, Patel V, Thara R, Gureje O. Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull 2008;34:229-244.
59. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clin Trials 2008;5:225-239.
60. White IR, Higgins JP, Wood AM. Allowing for uncertainty due to missing data in meta-analysis - part 1: two-stage methods. Stat Med 2008;27:711-727.
61. White IR, Welton NJ, Wood AM, Ades AE, Higgins JP. Allowing for uncertainty due to missing data in meta-analysis - part 2: hierarchical models. Stat Med 2008;27:728-745.
62. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-106.
63. Prakash A, Risser RC, Mallinckrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract 2008;62:1147-1158.
64. Dunn G, Maracy M, Tomenson B. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Stat Methods Med Res 2005;14:369-395.
65. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087.
66. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
67. Kapur S. How antipsychotics become anti-"psychotic"- from dopamine to salience to psychosis. Trends Pharmacol Sci 2004;25:402-406.
68. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009;120:102-111.
69. Greenberg RP, Fisher S. Suspended judgement. Seeing through the double-masked design: a commentary. Control Clin Trials 1994;15:244-246.
70. Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. Am J Psychiatry 2010;167:250-252.
71. Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials 2010;7:246-255.